News
European Commission approves Xolair as an add-on therapy with intranasal corticosteroids for the treatment of severe chronic rhinosinusitis with nasal polyps. - Novartis
Novartis announced that the European Commission (EC) has approved Xolair (omalizumab) as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with INC does not provide adequate disease control. Phase III studies have shown that Xolair reduces nasal polyp size (defined by Nasal Polyp Score; NPS) and improves symptoms and quality of life in patients with CRSwNP5. Xolair is the first treatment for CRSwNP specifically targeting and blocking immunoglobulin E (IgE), a key driver in the inflammatory pathway of this disease.
Condition: Nasal Polyps
Type: drug